SCHEMBL2273166

SCHEMBL2273166

Cc1cccc(Oc2ccc(C(=O)O)c(NC(=O)c3ccccc3)c2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 2/20 0.61
MAPK1 P28482 1/20 0.61
MEN1 O00255 5/20 0.56
KMT2A Q03164 5/20 0.56
HPSE Q9Y251 1/20 0.55
PYGM P11217 3/20 0.55
PYGL P06737 1/20 0.55
MAPT P10636 2/20 0.55
HTT P42858 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
TDP1 Q9NUW8 2/20 0.54
PKM P14618 1/20 0.54
GRIK1 P39086 1/20 0.54
ALDH1A1 P00352 1/20 0.53
NR1H4 Q96RI1 1/20 0.53
SERPINE1 P05121 1/20 0.53
GALK1 P51570 1/20 0.53
CASP6 P55212 1/20 0.53
MCL1 Q07820 1/20 0.53
PLEC Q15149 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2273349 0.94 MEN1 (0.61) GFERMAPK1MEN1KMT2APYGM
SCHEMBL2273044 0.90 CYP2C9 (0.61) GFERMEN1KMT2APYGMPYGL
SCHEMBL2271588 0.90 SERPINE1 (0.64) MEN1KMT2AHPSEPYGMPYGL
SCHEMBL2288393 0.89 MAPK1 (0.67) GFERMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL2275467 0.89 CYP2C9 (0.63) GFERMAPK1MEN1KMT2AHPSE
SCHEMBL2272040 0.88 PGR (0.69) MEN1KMT2AHPSEPYGMPYGL
SCHEMBL2271920 0.86 SERPINE1 (0.57) MEN1KMT2AHPSEPYGMPYGL
SCHEMBL2269896 0.86 TDP1 (0.58) MEN1KMT2AHPSEPYGMPYGL
SCHEMBL2274217 0.86 CYP2C9 (0.57) GFERMAPK1MEN1KMT2AHPSE
SCHEMBL2269555 0.85 HPSE (0.55) MEN1KMT2AHPSEPYGMPYGL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 GFER 823/4885MAPK1 168/4885MEN1 3105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.